July 3, 2025
admin
Anthem Biosciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate @ Chanakyanipothi.com
+A legacy of 31 Years.
+India`s Oldest Investment & IPO website.
+Most Trusted by Investors across India.
Table of Contents
- GMP
- Reviews
- Subscription
- Allotment
What is the latest news relating to Anthem Biosciences IPO?
Soon, the company will enter the capital market.
Anthem Biosciences IPO Subscription Status
Anthem Biosciences IPO (Day 1) |
|||||
| QIB | B HNI X | S HNI X | NII X | RII X | Total X |
| Applications: Subcription Review: . |
|||||
Who is the promoter of Anthem Biosciences IPO?
The promoters of the company are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj and they hold 77.23% of the pre-IPO capital of the company.
What are the Objects of Anthem Biosciences IPO?
The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.
What is the business of Anthem Biosciences?
About Anthem Biosciences Limited
Innovating Molecule to Market Since 2006
Founded in 2006, Anthem Biosciences Limited is a cutting-edge, innovation-led Contract Research, Development & Manufacturing Organization (CRDMO). With fully integrated operations spanning drug discovery, development, and commercial manufacturing, it partners with some of the world’s most forward-thinking biotech startups and global pharmaceutical leaders.
Its specialty lies in fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars—serving high-impact healthcare markets around the world.
Global Reach. Scientific Depth.
-
44+ countries served, including the U.S., Europe, and Japan
-
550+ customers across CRDMO and specialty ingredients businesses
-
Trusted by both emerging biotech innovators and top-tier pharmaceutical giants
Pipeline Highlights (as of September 30, 2024):
-
196 active R&D and manufacturing projects
-
170 discovery projects (284 molecules synthesized)
-
132 early-phase & 16 late-phase development programs
-
13 commercial manufacturing projects (covering 10 molecules)
-
-
APIs and intermediates manufactured for 10 commercial molecules, all supported from the discovery stage
Intellectual Property & Innovation
-
8 granted patents (1 in India, 7 overseas)
-
24 pending global applications, including key process patents in glycolipid synthesis and GLP-1 analogues
Powered by People
Its team of over 600 skilled professionals includes:
-
Medicinal chemists
-
Microbiologists & molecular biologists
-
Biochemists & chemical engineers
-
In-vivo non-clinical research specialists
Anthem Biosciences is not just a service provider—it is a scientific partner committed to transforming molecules into medicines that impact lives across the globe.
Anthem Biosciences IPO GMP grey market premium, review, Subscription, allotment, listing estimate
|
Anthem Biosciences IPO Details |
|
| IPO opens on | July 2025 |
| IPO closes on | July 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | ? Shares / Rs Crore |
| * Fresh Issue | ? Shares / Rs Crore |
| * Offer for Sale | – shares/ Rs. Crore |
| Face Value per share: | Rs. 10 |
| Price Band | Rs. |
| Retail Discount | Rs 0 per share |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | Shares |
| Listing will at | BSE, NSE |
|
Shares offered in |
Shares | Rs. in Crore |
| QIB (50 %) | ? | |
| NII (15 %) | ? | |
| RII (35 %) | ||
| Employees | – | |
| Total Shares | ? | |
| Retail portion will be oversubscribed by | 2655743 Forms. | |
| How to apply in Anthem Biosciences IPO? | Amount Rs. |
|
| Min Retail Application | Shares | |
| Max Retail Application | Shares | |
| Small HNI (Min) | Shares | |
| Small HNI (Max) | Shares | |
| Big HNI Application | Shares | |
|
What is the timetable of Anthem Biosciences IPO? |
|
| IPO opens on | 25 June 2025 |
| IPO Closes on | 27 June 2025 |
| IPO Allotment on | 30 June 2025 |
| Unblocking of ASBA | 1 July 2025 |
| Credit of Shares | 1 July 2025 |
| Listing on | 2 July 2025 |
| Registered Office of Anthem Biosciences | |
| Anthem Biosciences Limited No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099 |
|
| The Lead Managers of the IPO Jm Financial Limited Citigroup Global Markets India Pvt Ltd |
|
| Registrar to IPO | |
| Kfin Technologies Limited |
Anthem Biosciences Financials
| Period Ended | 30-Sep-24 | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
| Assets | 2,692.51 | 2,398.11 | 2,014.46 | 1,618.87 |
| Revenue | 910.85 | 1,483.07 | 1,133.99 | 1,280.24 |
| Profit After Tax | 244.31 | 367.31 | 385.19 | 405.54 |
| EBITDA | 327.5 | 519.96 | 446.05 | 587.31 |
| Net Worth | 2,204.37 | 1,924.66 | 1,740.67 | 1,355.00 |
| Reserves and Surplus | 2,095.49 | 1,815.39 | 1,628.88 | 1,347.64 |
| Total Borrowing | 131.26 | 232.53 | 125.06 | 35.49 |
| Amount in Rs. Crore | ||||
| KPI | Values |
| ROE | 20.04% |
| ROCE | 25.22% |
| Debt/Equity | 0.12 |
| RoNW | 20.03% |
| PAT Margin | 24.77% |
| EBITDA Margin | 36.25% |
How Anthem Biosciences IPO compares with the Peers?
| Company Name | P/E (x) | RoNW (%) |
| Anthem Biosciences Limited | 20.03 | |
| Syngene International Ltd | 67.23 | 12.95 |
| Sai Life Sciences Limited | 168.9 | 8.89 |
| Suven Life Sciences Ltd. | 105.7 | 15.86 |
| Divi’s Laboratories Limited | 97.03 | 12.15 |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Anthem Biosciences IPO Review
- Market Analysis by Nagaraj Shetti
- Stock Market today by Vaishali Parekh
- Analysis by Kotak Securities
- Market Analysis by HDFC Securities
- Technical Analysis by Kotak Securities
- Technical Analysis by Samco Securities
- Reliance, Target & Stoploss
- Gold Analysis
- FII buy-Sell
- Technical Analysis
- Calls for the Day
- Currency Analysis
Quicklinks
